Abstract
Autism Spectrum Disorder (ASD) is a range of neurodevelopmental conditions characterized by impaired social interaction, learning, and restricted or repetitive behaviors. The underlying causes of ASD are still debated, but researchers have found many physiological traits like gut problems and impaired immune system to help understand the etiology of ASD. Cerebrospinal fluid (CSF) plays a critical role in maintaining the homeostasis of the neuronal environment and has, therefore, been analyzed in multiple conditions impacting the central nervous system. The study of CSF is crucial to understanding neurological disorders as its composition changes with the disorders, and these changes may indicate various disorder-related physiological mechanisms. For this systematic review, we searched PubMed, Scopus, and Web of Science for studies published between 1977 and 2025 and selected 49 studies after manual screening. We took stock of the evidence supporting the hypothesis that ASD alters the properties and composition of CSF. We systematically report on the different attributes of CSF in the ASD population that could be potential biomarkers and assist in understanding the origins and progression of ASD.
We found that in CSF, immune markers, proteins, extra-axial CSF, folate, oxytocin, and vasopressin showed changes in ASD compared to the neurotypicals. We observed gaps in the literature due to variations in age and sample size and noted biases related to sex (i.e., samples are predominantly including male participants) and age (i.e., a handful of studies were conducted on adults). Our review highlights the need for more research on CSF in ASD to improve our understanding of this disorder and identify CSF biomarkers.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by a pilot grant from the Carolina Autism & Neurodevelopment (CAN) Research Center (PI: Christian O Reilly) at the University of South Carolina.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Email: Christian O’Reilly, christian.oreilly{at}sc.edu
We have made significant changes to our manuscript. We included papers from PubMed from January 2024 to March 31, 2025, and added two more databases, Scopus and Web of Science, with studies from 1977 to March 2025. We have also improved the text at many places in our manuscript, such as sorting the abbreviations below each table in alphabetical order. We updated Figure 1 (PRISMA chart) and Figure 2 (summary chart)because new papers/new databases were added. We updated the statistics at different places in the Discussion section to incorporate the data related to new papers. We added a paragraph on the CSF analysis method after each category (immune markers, folate, protein/amino acids, monoamines, and others). We added observations regarding age and sex in the Gaps section: 1.In 9/49 (18%) of the ASD samples, there was a huge variation in the age range (such as 5.3 to 19 years (Parker et al., 2018), 1 to 22 years (Nordin et al., 1998), 2 to 23 years (Perry, 1978)) making it hard to do any reliable age-based analysis. 2. We added Figure 7 to show the proportion of males and females in each category between 1977 and 2025. We created two scatterplots (Figure 4,top and bottom) with the percentage of significant molecules versus years. We found that six out of nine (67%) of the monoamine neurotransmitter studies were conducted before 1995, and 4/9 (44%) of them used the high-performance liquid chromatography (HPLC) method for analysis, 85% (6/7) of all the immune marker studies were carried out after 2000; 50% of them used multiplex/bead multiplex immunoassays (MIA/BMIA), and 50% used the enzyme or enzyme-linked immunoabsorbent assays (EIA/ELISA) method. Also, 6/37 studies before 2000 were inconclusive (0%), but none were after 2000. We further commented on the effect of sample size. We updated Table 7, which divides the studies according to the sample size. We defined the percentage of significant molecules (PSM) by taking the ratio of the number of significantly changed molecule levels over the total number of molecules assayed. We tested whether the percentage of significant molecules reported by studies was directly associated with their sample size for each category. We tested the relation between PSM and sample size, analysis method and PSM with method. We did not find any statistically significant relation between PSM and (sample size + method) or PSM and method.
Data Availability
All data produced in the present work are contained in the manuscript.
